-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
New drug research and development has the characteristics of long cycle, high cost and high risk.
The application of AI in drug research and development can greatly shorten the research and development cycle, reduce research and development costs, and improve the success rate of drug research and development
.
In recent years, more and more companies have used AI technology to deploy new drug research and development
.
Entering 2022, the field of AI new drugs is still hot, and many multinational pharmaceutical companies and local pharmaceutical companies are increasing their layout through "marriage" cooperation
.
For example, among multinational pharmaceutical companies, on January 7, Sanofi and Exscientia jointly announced that the two parties had reached an advance payment of 100 million US dollars and a total of about 5.
2 billion US dollars of cooperation
.
The parties will leverage Exscientia's end-to-end AI-driven platform utilizing actual patient samples to develop up to 15 novel small molecule drug candidates in oncology and immunology
.
It is understood that the cooperation between Sanofi and Exscientia is also traceable.
As early as 2016, the two hands announced "holding hands"
.
In 2019, Sanofi licensed Exscientia to develop novel bispecific small molecule drug candidates capable of targeting two distinct targets related to inflammation and immunity
.
On the same day, Merck announced a $610 million partnership with Absci
.
The two companies will utilize Absci's AI-driven integrated drug development technology platform for drug development
.
It is understood that Absci will deploy its Bionic Protein non-standard amino acid technology to produce enzymes for Merck biomanufacturing applications
.
In mid-January, Pfizer announced an expansion of its existing strategic cooperation with PostEra to establish an artificial intelligence laboratory (AI Lab) to jointly advance the development of new drugs
.
Based on Pfizer data and PostEra's pioneering innovations in generative chemistry and synthesis-aware design, the AI Lab will utilize novel machine learning techniques for medicinal chemistry research
.
In addition, AstraZeneca recently announced that it has reached a research and development cooperation with Benevolent AI and Scorpion Therapeutics.
.
According to the agreement, AstraZeneca will use the two AI drug development platforms to accelerate the development of new drugs for systemic lupus erythematosus (SLE) and heart failure (HF), as well as to develop innovative anti-cancer treatments for difficult-to-treat transcription factors
.
In addition to the above-mentioned multinational companies, this year, Amgen and others have successively deployed AI pharmaceuticals
.
In early January, Amgen and Generate, an artificial intelligence (AI) company owned by Boston-based venture capital Flagship Pioneering, jointly announced that the two parties would collaborate on five therapeutic programs aimed at combining Generate’s machine learning algorithms with Amgen’s drug development capabilities.
, in order to obtain multispecific drugs
.
Throughout the country, local pharmaceutical companies are also actively deploying in the field of AI pharmaceuticals
.
On January 11, Fosun Pharma and Insilico Technologies announced a strategic cooperation to jointly promote AI-driven multi-target drug research and development cooperation
.
Then, on February 17, Fosun Pharma and Insilico Technologies announced that they have nominated the preclinical candidate compound ISM004-1057D for the cooperation project for new tumor immunotherapy
.
At present, the two parties are jointly conducting research for the application of new drug clinical trials, so as to advance the project to the clinical trial stage as soon as possible
.
For another example, at the end of January this year, Unknown Jun and Qihui Biological jointly announced a strategic cooperation.
The two parties will carry out in-depth cooperation in the fields of intestinal flora extraction, purification, clinical application and AI pharmaceuticals
.
In general, cooperation in the field of AI pharmaceuticals has been very hot this year
.
It is worth mentioning that although the advantages of AI pharmaceuticals are prominent, the results of successful cooperation are few
.
In this regard, the industry believes that the first drug candidate after the cooperation between Insilicon and Fosun Pharma will be injected into the verification of AI-pharmaceutical cooperation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The application of AI in drug research and development can greatly shorten the research and development cycle, reduce research and development costs, and improve the success rate of drug research and development
.
In recent years, more and more companies have used AI technology to deploy new drug research and development
.
Entering 2022, the field of AI new drugs is still hot, and many multinational pharmaceutical companies and local pharmaceutical companies are increasing their layout through "marriage" cooperation
.
For example, among multinational pharmaceutical companies, on January 7, Sanofi and Exscientia jointly announced that the two parties had reached an advance payment of 100 million US dollars and a total of about 5.
2 billion US dollars of cooperation
.
The parties will leverage Exscientia's end-to-end AI-driven platform utilizing actual patient samples to develop up to 15 novel small molecule drug candidates in oncology and immunology
.
It is understood that the cooperation between Sanofi and Exscientia is also traceable.
As early as 2016, the two hands announced "holding hands"
.
In 2019, Sanofi licensed Exscientia to develop novel bispecific small molecule drug candidates capable of targeting two distinct targets related to inflammation and immunity
.
On the same day, Merck announced a $610 million partnership with Absci
.
The two companies will utilize Absci's AI-driven integrated drug development technology platform for drug development
.
It is understood that Absci will deploy its Bionic Protein non-standard amino acid technology to produce enzymes for Merck biomanufacturing applications
.
In mid-January, Pfizer announced an expansion of its existing strategic cooperation with PostEra to establish an artificial intelligence laboratory (AI Lab) to jointly advance the development of new drugs
.
Based on Pfizer data and PostEra's pioneering innovations in generative chemistry and synthesis-aware design, the AI Lab will utilize novel machine learning techniques for medicinal chemistry research
.
In addition, AstraZeneca recently announced that it has reached a research and development cooperation with Benevolent AI and Scorpion Therapeutics.
.
According to the agreement, AstraZeneca will use the two AI drug development platforms to accelerate the development of new drugs for systemic lupus erythematosus (SLE) and heart failure (HF), as well as to develop innovative anti-cancer treatments for difficult-to-treat transcription factors
.
In addition to the above-mentioned multinational companies, this year, Amgen and others have successively deployed AI pharmaceuticals
.
In early January, Amgen and Generate, an artificial intelligence (AI) company owned by Boston-based venture capital Flagship Pioneering, jointly announced that the two parties would collaborate on five therapeutic programs aimed at combining Generate’s machine learning algorithms with Amgen’s drug development capabilities.
, in order to obtain multispecific drugs
.
Throughout the country, local pharmaceutical companies are also actively deploying in the field of AI pharmaceuticals
.
On January 11, Fosun Pharma and Insilico Technologies announced a strategic cooperation to jointly promote AI-driven multi-target drug research and development cooperation
.
Then, on February 17, Fosun Pharma and Insilico Technologies announced that they have nominated the preclinical candidate compound ISM004-1057D for the cooperation project for new tumor immunotherapy
.
At present, the two parties are jointly conducting research for the application of new drug clinical trials, so as to advance the project to the clinical trial stage as soon as possible
.
For another example, at the end of January this year, Unknown Jun and Qihui Biological jointly announced a strategic cooperation.
The two parties will carry out in-depth cooperation in the fields of intestinal flora extraction, purification, clinical application and AI pharmaceuticals
.
In general, cooperation in the field of AI pharmaceuticals has been very hot this year
.
It is worth mentioning that although the advantages of AI pharmaceuticals are prominent, the results of successful cooperation are few
.
In this regard, the industry believes that the first drug candidate after the cooperation between Insilicon and Fosun Pharma will be injected into the verification of AI-pharmaceutical cooperation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
